Gilead Sciences (GILD) DIvidends Date & History

Key Takeaways

• GILD pays a quarterly dividend of $0.82 per share, an annualized $3.28 per share.
• The stock's dividend yield is roughly 2.5%, modestly above the broader healthcare-sector average.
• Gilead Sciences has raised its dividend for 10 consecutive years, with a five-year annualized growth rate of about 3%.
• The payout ratio of approximately 44.7% of earnings and about 31% of free cash flow (cash a company generates after operating and capital expenses) suggests the dividend is well covered.
• The profile suits income-oriented and conservative investors seeking dependable, slowly growing cash distributions.

Dividend Overview

Gilead Sciences, Inc. operates as a biopharmaceutical company focused on antiviral and oncology therapies, and it has returned capital to shareholders through a regular dividend since 2015. The company currently pays a quarterly dividend of $0.82 per share, which annualizes to $3.28 per share and equates to a dividend yield near 2.5%. Payments are distributed on a quarterly schedule, typically with an ex-dividend date in the middle of the final month of each calendar quarter and payment following roughly two weeks later. Gilead is best characterized as a dividend growth stock with a moderate yield rather than a high-yield income vehicle. Its annual increases have been steady but relatively small, reflecting a management approach that prioritizes reinvestment in research and development and strategic acquisitions while still rewarding shareholders with a dependable, slowly rising payout.

Dividend History and Growth

Gilead initiated its dividend in 2015 and has increased it every year since, reaching a 10-year streak of consecutive annual dividend increases. The company has typically announced its raise each February, lifting the quarterly payment by a low-to-mid single-digit percentage. Recent payments illustrate the pace: the quarterly rate rose from $0.75 in 2023, to $0.77 in 2024, to $0.79 in 2025, and to $0.82 beginning in March 2026. Over the past five years, the dividend has compounded at roughly 3% annually. This trajectory points to a disciplined, consistent payout strategy rather than an aggressive one, reflecting the company's commitment to a durable, sustainable distribution over time even as it navigates patent cycles and reinvests heavily in its drug pipeline.

Dividend Sustainability and Payout Ratio

The dividend appears well supported by current financials. Gilead's payout ratio is roughly 44.7% of trailing earnings and about 31% of free cash flow, levels that are comfortably below thresholds that would signal strain. This low cash-flow payout ratio provides a meaningful cushion for the dividend even if earnings fluctuate, while also leaving ample room for research, share repurchases, and debt management. The company's balance sheet and diversified product portfolio, including its HIV franchise and growing oncology business, further reinforce payment stability. Although earnings-based payout ratios can swing in periods of one-time charges or acquisition costs, the underlying cash-generation profile has consistently supported the dividend, indicating a low likelihood of a cut under current operating conditions.

Dividend Compared to Industry Peers

Within the large-cap biopharmaceutical and healthcare space, Gilead's roughly 2.5% yield is respectable but not among the highest. For context, mature pharmaceutical peers such as ABBV (AbbVie), PFE (Pfizer), and BMY (Bristol Myers Squibb) often carry higher yields, while biotech-oriented names such as AMGN (Amgen) and diversified healthcare leaders such as JNJ (Johnson & Johnson) sit in a broadly similar range. Gilead's yield lands near the middle of this peer group, and its roughly 3% annual growth rate is comparatively modest. Investors weighing Gilead against peers will find a payout that trades some yield and growth speed for a strong free-cash-flow cushion and a decade-long record of uninterrupted increases.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener can help identify dividend stocks, income-focused investments, trending stocks, breakout candidates, and emerging market opportunities far more efficiently than manual screening. Explore the AI Screener to build watchlists and uncover opportunities aligned with your dividend and income strategy.

Is This Stock Attractive for Dividend Investors?

Gilead's dividend profile is likely to appeal most to income-oriented and conservative investors who prioritize reliability and modest growth over maximum yield. The roughly 2.5% yield, 10-year streak of increases, and low free-cash-flow payout ratio make it a candidate for long-term holders seeking a dependable, slowly compounding income stream. Dividend growth investors may find the roughly 3% annual increase relatively modest compared with faster-growing peers, and investors seeking high current income will encounter more generous yields elsewhere in the sector. The payout's durability is reinforced by the company's steady cash generation and diversified revenue base, though pharmaceutical companies inherently carry patent-expiration and pipeline risk that can affect long-term growth. Overall, Gilead may suit balanced, long-horizon dividend investors more than aggressive income or rapid-growth seekers.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations